Brian M. Silver, J.D.
Chief Financial Officer
“It is a privilege to work with investors to support efforts to bring cancer treatments from our labs to the patients who need them.”
Brian Silver, J.D., is the Chief Financial Officer at TScan Therapeutics. Prior to joining TScan, Brian served as Freeline Therapeutics’ CFO and Head of Corporate Development, overseeing the Company’s financial, corporate legal and business development operations, including corporate strategy, BD&L, legal and compliance, investor relations, accounting, financial planning and analysis, IT, tax and treasury. In just over two years at Freeline, Brian raised over $300 million in capital, via a crossover financing as well as in one of the largest ever Nasdaq IPOs for a UK-based clinical-stage biotech company.
Before joining Freeline, Brian was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to that, Brian was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell.
Brian has worked with a range of large and emerging pharmaceutical and biotechnology clients during his 25-year Wall Street career. His investment banking and corporate law advisory experience includes dozens of M&A and financing transactions across all capital markets, including IPOs, follow-ons, high yield and investment grade debt, and royalty financings. His M&A experience includes sell side and buy side transactions and leveraged buyouts, as well as reverse mergers and corporate restructurings.
Brian received a B.A. with honors from Harvard College and a J.D. with honors from the University of Chicago Law School.